We are focused on bringing innovation to the treatment of cachexia with a vision to transform care for an under-served and vulnerable patient population, prolong and improve the quality of their lives, restore their dignity and ease the burden for the patient, carer and provider.
Cachexia is a wasting disease that accompanies cancer and other serious chronic illnesses and is associated with significant morbidity and mortality. Despite its prevalence and devastating clinical effects, there is no approved drug for the treatment or prevention of cancer-related cachexia.
Our approach focuses on a class of agents that have multiple effects on the fundamental biology of cachexia to reduce catabolism (weight loss), increase and maintain anabolism (weight gain, particularly muscle mass gain), decrease fatigue, and stimulate appetite.
Our lead product, MT-102 (Espindolol) is in clinical development for cancer-related cachexia. It has demonstrated promising results in a Phase II trial and further trials are planned. Over time, our goal is to assemble a product pipeline with potential in treating cachexia associated with a range of conditions.
Our founders, Professor Andrew Coats and Professor Stefan Anker, are world-leading physicians in cachexia research, and the company is led by a management team and board with significant global experience in the development of new therapeutics across multiple indications.